Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CASi-400
- Development stage
- Preclinical
- Lead developer
- Switch Therapeutics
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
CASi-400 is a preclinical-stage small interfering RNA (siRNA) therapeutic being developed by Switch Therapeutics. It is built upon the company's proprietary Conditionally Activated siRNA (CASi) platform, which utilizes a unique structural approach to enhance the delivery, stability, and potency of RNA interference (RNAi) molecules. The CASi platform is specifically designed to enable efficient gene silencing in the central nervous system (CNS) and other tissues. While the specific molecular target and primary disease indication for CASi-400 have not yet been disclosed by the developer, the program represents a key asset in Switch Therapeutics' pipeline of next-generation RNAi therapies.
Beyond the preview
Go deeper on CASi-400.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CASi-400.